Catalyst Pharmaceuticals Inc
CPRX22.830USD
+1.270+5.89%
Market hours （ET）Quotes delayed by 15 min
2.81BMarket Cap
12.93P/E TTM
More Details of Catalyst Pharmaceuticals Inc Company
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing first-in-class medicines that address rare and difficult to treat diseases. Its flagship commercial product is FIRDAPSE (amifampridine) tablets 10 milligrams (mg), approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) for adults and for children ages six to seventeen. The Company is also marketing FYCOMPA (perampanel) CIII as a prescription medication used alone or with other medicines to treat focal onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. Its portfolio also includes AGAMREE (vamorolone) an oral suspension 40 mg/ml for the treatment of Duchenne Muscular Dystrophy (DMD). The vamorolone is a corticosteroid treatment for patients suffering from DMD.
Catalyst Pharmaceuticals Inc Info
Ticker SymbolCPRX
Company nameCatalyst Pharmaceuticals Inc
IPO dateNov 08, 2006
CEOMr. Richard J. (Rich) Daly
Number of employees181
Security typeOrdinary Share
Fiscal year-endNov 08
Address355 Alhambra Circle
CityCORAL GABLES
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code33134
Phone13055292522
Websitehttps://catalystpharma.com/
Ticker SymbolCPRX
IPO dateNov 08, 2006
CEOMr. Richard J. (Rich) Daly
Company Executives of Catalyst Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Patrick James Mcenany
Mr. Patrick James Mcenany
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
4.28M
-4.46%
Dr. Steven R. Miller, Ph.D.
Dr. Steven R. Miller, Ph.D.
Executive Vice President, Chief Operating Officer, and Chief Scientific Officer
Executive Vice President, Chief Operating Officer, and Chief Scientific Officer
1.06M
+11.58%
Mr. Donald A. Denkhaus
Mr. Donald A. Denkhaus
Independent Director
Independent Director
495.08K
--
Dr. David S. Tierney, M.D.
Dr. David S. Tierney, M.D.
Independent Director
Independent Director
379.62K
+6.75%
Mr. Brian D. Elsbernd, J.D.
Mr. Brian D. Elsbernd, J.D.
Chief Compliance Officer, Chief Legal Officer
Chief Compliance Officer, Chief Legal Officer
271.04K
+43.74%
Mr. Richard J. (Rich) Daly
Mr. Richard J. (Rich) Daly
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
226.79K
+13.53%
Dr. Gary Ingenito, M.D., Ph.D.
Dr. Gary Ingenito, M.D., Ph.D.
Chief Medical Officer and Regulatory Officer
Chief Medical Officer and Regulatory Officer
68.87K
--
Dr. Preethi Sundaram, Ph.D.
Dr. Preethi Sundaram, Ph.D.
Chief Strategy Officer
Chief Strategy Officer
41.08K
-8.72%
Ms. Molly Harper
Ms. Molly Harper
Lead Independent Director
Lead Independent Director
6.75K
--
Ms. Tamar Thompson
Ms. Tamar Thompson
Independent Director
Independent Director
1.41K
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Patrick James Mcenany
Mr. Patrick James Mcenany
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
4.28M
-4.46%
Dr. Steven R. Miller, Ph.D.
Dr. Steven R. Miller, Ph.D.
Executive Vice President, Chief Operating Officer, and Chief Scientific Officer
Executive Vice President, Chief Operating Officer, and Chief Scientific Officer
1.06M
+11.58%
Mr. Donald A. Denkhaus
Mr. Donald A. Denkhaus
Independent Director
Independent Director
495.08K
--
Dr. David S. Tierney, M.D.
Dr. David S. Tierney, M.D.
Independent Director
Independent Director
379.62K
+6.75%
Mr. Brian D. Elsbernd, J.D.
Mr. Brian D. Elsbernd, J.D.
Chief Compliance Officer, Chief Legal Officer
Chief Compliance Officer, Chief Legal Officer
271.04K
+43.74%
Mr. Richard J. (Rich) Daly
Mr. Richard J. (Rich) Daly
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
226.79K
+13.53%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
13.25%
The Vanguard Group, Inc.
7.07%
State Street Investment Management (US)
5.21%
McEnany (Patrick James)
3.48%
Renaissance Technologies LLC
2.65%
Other
68.34%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
13.25%
The Vanguard Group, Inc.
7.07%
State Street Investment Management (US)
5.21%
McEnany (Patrick James)
3.48%
Renaissance Technologies LLC
2.65%
Other
68.34%
Shareholder Types
Shareholders
Proportion
Investment Advisor
45.16%
Investment Advisor/Hedge Fund
25.00%
Hedge Fund
8.17%
Individual Investor
6.16%
Research Firm
5.16%
Pension Fund
1.35%
Bank and Trust
0.49%
Private Equity
0.34%
Family Office
0.16%
Other
8.02%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
691
105.03M
85.46%
-2.39M
2025Q2
680
109.05M
89.10%
-4.69M
2025Q1
693
109.47M
89.76%
-3.79M
2024Q4
658
108.09M
89.06%
-2.57M
2024Q3
628
104.82M
88.36%
-8.18M
2024Q2
597
106.41M
90.13%
-15.99M
2024Q1
590
105.68M
89.66%
-4.79M
2023Q4
569
93.52M
87.71%
-15.08M
2023Q3
548
90.12M
84.55%
-19.61M
2023Q2
542
91.66M
86.51%
-22.59M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
16.29M
13.31%
-124.58K
-0.76%
Jun 30, 2025
The Vanguard Group, Inc.
8.74M
7.14%
+268.10K
+3.16%
Jun 30, 2025
State Street Investment Management (US)
5.48M
4.48%
-52.05K
-0.94%
Jun 30, 2025
McEnany (Patrick James)
4.28M
3.5%
-200.00K
-4.46%
Jun 09, 2025
Renaissance Technologies LLC
3.25M
2.66%
+295.20K
+9.99%
Jun 30, 2025
Deerfield Management Company, L.P.
2.88M
2.35%
-542.67K
-15.86%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.87M
2.34%
+101.13K
+3.66%
Jun 30, 2025
Fundsmith LLP
2.71M
2.21%
+557.81K
+25.93%
Jun 30, 2025
Morgan Stanley & Co. LLC
2.35M
1.92%
+715.39K
+43.77%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
1.91M
1.56%
-279.90K
-12.80%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
iShares Neuroscience and Healthcare ETF
3.94%
Invesco Biotechnology & Genome ETF
2.64%
Invesco S&P SmallCap Health Care ETF
1.44%
Janus Henderson Small Cap Growth Alpha ETF
1.36%
ETC 6 Meridian Small Cap Equity ETF
1.15%
Invesco S&P SmallCap 600 GARP ETF
1.13%
VictoryShares Small Cap Free Cash Flow ETF
0.96%
Invesco S&P SmallCap 600 Pure Growth ETF
0.9%
First Trust Small Cap US Equity Select ETF
0.9%
SPDR S&P Biotech ETF
0.79%
View more
iShares Neuroscience and Healthcare ETF
Proportion3.94%
Invesco Biotechnology & Genome ETF
Proportion2.64%
Invesco S&P SmallCap Health Care ETF
Proportion1.44%
Janus Henderson Small Cap Growth Alpha ETF
Proportion1.36%
ETC 6 Meridian Small Cap Equity ETF
Proportion1.15%
Invesco S&P SmallCap 600 GARP ETF
Proportion1.13%
VictoryShares Small Cap Free Cash Flow ETF
Proportion0.96%
Invesco S&P SmallCap 600 Pure Growth ETF
Proportion0.9%
First Trust Small Cap US Equity Select ETF
Proportion0.9%
SPDR S&P Biotech ETF
Proportion0.79%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
